Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Hold” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have earned a consensus recommendation of “Hold” from the three brokerages that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating. The average 1 year price objective among brokers that have covered the stock in the last year is $28.00.

Separately, StockNews.com upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ATRA. BNP Paribas Financial Markets boosted its stake in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Atara Biotherapeutics during the 4th quarter valued at $41,000. Harbor Capital Advisors Inc. boosted its stake in Atara Biotherapeutics by 368.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 164,206 shares during the last quarter. Josh Arnold Investment Consultant LLC boosted its stake in Atara Biotherapeutics by 17.6% during the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Redmile Group LLC boosted its stake in Atara Biotherapeutics by 3.8% during the 3rd quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after purchasing an additional 232,690 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Down 0.8 %

Atara Biotherapeutics stock opened at $0.68 on Thursday. Atara Biotherapeutics has a 52 week low of $0.20 and a 52 week high of $3.02. The business has a 50-day simple moving average of $0.71 and a 200 day simple moving average of $0.75. The stock has a market cap of $82.43 million, a price-to-earnings ratio of -0.26 and a beta of 0.69.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, March 28th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.05. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 3,220.88%. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $2.45 million. On average, research analysts anticipate that Atara Biotherapeutics will post -1.3 earnings per share for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.